Trial reportScientific reports2022
Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2.
Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Suppression of microbial burden to reduce pneumonia in critical illness: the SMURF feasibility pilot study.Critical care (London, England) · 2026Trial
- Photodynamic nasal SARS-CoV-2 decolonization shortens infectivity and influences specific T-Cell responses.Frontiers in cellular and infection microbiology · 2023Trial
- Human Coronavirus Photodynamic Inactivation and In Silico Mechanisms Induced by Ga(III) vs. Zn(II) Phthalocyanines.Viruses · 2026Article
- Syntheses, DNA interactions, and photodynamic antimicrobial properties of near-infrared indolium carbocyanine dyes.RSC advances · 2026Article
- Light-based therapy of infected wounds: a review of dose considerations for photodynamic microbial inactivation and photobiomodulation.Journal of biomedical optics · 2025Review
- Femtosecond pulsed laser photodynamic therapy activates melanin and eradicates malignant melanoma.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- In vitro photoinactivation effectiveness of a portable LED device aimed for intranasal photodisinfection and a photosensitizer formulation comprising methylene blue and potassium iodide against bacterial, fungal, and viral respiratory pathogens.Lasers in medical science · 2024Article
- Application of methylene blue for the prevention and treatment of COVID-19: A narrative review.Iranian journal of basic medical sciences · 2024Review
- Impact of nasal photodisinfection on SARS-CoV-2 infection in an industrial workplace.Public health in practice (Oxford, England) · 2023Article
- Selective, broad-spectrum antiviral photodynamic disinfection with dicationic imidazolyl chlorin photosensitizers.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2023Article
- Dominant CT Patterns and Immune Responses during the Early Infection Phases of Different SARS-CoV-2 Variants.Viruses · 2023Observational
- COVID-19 Incidence and Vaccine Effectiveness in University Staff, 1 March 2020-2 April 2022.Vaccines · 2023Article
- Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants.Pathogens (Basel, Switzerland) · 2023Article
- Effective Biofilm Eradication on Orthopedic Implants with Methylene Blue Based Antimicrobial Photodynamic Therapy In Vitro.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of therapeutic options to fight Covid-19 has contributed to the current global pandemic. Despite the emergence of effective vaccines, development of broad-spectrum antiviral treatment remains a significant challenge, in which antimicrobial photodynamic therapy (aPDT) may play a role, especially at early stages of infection. aPDT of the nares with methylene blue (MB) and non-thermal light has been successfully utilized to inactivate both bacterial and viral pathogens in the perioperative setting. Here, we investigated the effect of MB-aPDT to inactivate human betacoronavirus OC43 and SARS-CoV-2 in vitro and in a proof-of-principle COVID-19 clinical trial to test, in a variety of settings, the practicality, technical feasibility, and short-term efficacy of the method. aPDT yielded inactivation of up to 6-Logs in vitro, as measured by RT-qPCR and infectivity assay. From a photo-physics perspective, the in vitro results suggest that the response is not dependent on the virus itself, motivating potential use of aPDT for local destruction of SARS-CoV-2 and its variants. In the clinical trial we observed variable effects on viral RNA in nasal-swab samples as assessed by RT-qPCR attributed to aPDT-induced RNA fragmentation causing falsely-elevated counts. However, the viral infectivity in clinical nares swabs was reduced in 90% of samples and undetectable in 70% of samples. This is the first demonstration based on quantitative clinical viral infectivity measurements that MB-aPDT is a safe, easily delivered and effective front-line technique that can reduce local SARS-CoV-2 viral load.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.